Centre Jean Perrin — Clinical Trial Site

193 Registered trials

97 Currently recruiting

Organisation

Centre Jean Perrin

Location

Clermont-Ferrand, France

Identifier

ORG-100010125

Address

58 Rue Montalembert, 63011, France

Departments

#1001: Medical Oncology
#1202: Oncologie
#2157: Oncology
033022: Oncologie Medicale - Cancerolo
03311: Service d' Oncologie Médicale
1204: Oncologie
1504:Medical Oncology
2000: Medical oncology
2152: Oncologie
2304 Oncology Medical
2314:Medecine
3099:Oncology
Cancérologie
Cardiology/EP
Chirurgie
Chirurgie gynécologique
Chirurgie Oncologique
Critical Care Medicine
Département d'oncologie
Département d'oncologie médicale
Département de Médecine
Department of Medical Oncology
Department of Oncology
Department of Urology
digestive oncology
Gynecological surgery
Internal Medicine
Médecine interne
Medecine nucleaire
Médecine Nucléaire/ Hépato-Gastro-Entérologie
medecine nuclear department
Médecine oncologique
Medical ICU
Medical Oncology
Medical Oncology Department
N/A
NA
Neurologie
NEUROLOGY
Nuclear Medicine
Oncologie
Oncologie digestive
Oncologie Médicale
Oncologue
Oncology
Oncology & Clin. Research
Oncology & Clinical Research
Oncology clinic
Oncology Department
Oncology for adults
Radiation oncology
Radiothérapie
Radiotherapy
Radiotherapy for adults
Radiotherapy Oncology
Réanimation/USC
Service d Oncologie
Service D Oncologie Medicale
Service d'Oncologie
Service d'Oncologie Médicale
Service d’Anesthésie et Réanimation
Service d’oncologie
Service de Médecine Intensive Réanimation
Service oncologie
Service Oncologie Medicale
Urologie

Clinical trials at this site (193)

Search interface

A clinical trial of sacituzumab tirumotecan to treat urothelial cancer (MK-2870-031) Recruiting

2024-520014-22-00 Locally advanced/metastatic urothelial carcinoma 5 2026-04-22
Trial assessing fianlimab plus cemiplimab plus chemotherapy or cemiplimab plus chemotherapy in patients with pleural mesothelioma Recruiting

2024-519208-29-00 Pleural mesothelioma 4 2026-04-02
A clinical trial to learn about the effects of AMO959 given with AAA617 and an androgen receptor pathway inhibitor (ARPI) in adults with PSM… Recruiting

2025-521859-23-00 PSMA-positive mCRPC with prior exposure to at least one 9 2026-03-31
A clinical study of opevesostat and standard hormone therapy in people with prostate cancer (MK-5684-004) Recruiting

2023-504957-11-00 Metastatic castration resistant prostate cancer 5 2026-03-24
Trial of T-DXd Versus SoC Chemotherapy as Adjuvant Treatment in Endometrial Cancer Recruiting

2024-519444-33-00 HER2-expressing endometrial cancer (IHC 3+/2+) 5 2026-03-12
Pasritamig With Docetaxel vs Docetaxel in Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting

2025-522713-29-00 Metastatic Castration-resistant Prostate Cancer (mCRPC) 5 2026-03-12
Testing two different drugs (sacituzumab-govitecan and trastuzumab-deruxtecan) combinations prescribed in an alterning pattern to patients w… Recruiting

2025-521909-40-00 Patients with metastatic or locally advanced HER2-low t 4 2026-01-28
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or Af… Recruiting

2025-522400-24-00 Metastatic urothelial cancer 10 2026-01-27
Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carc… Recruiting

2024-515023-11-00 Advanced Clear Cell Renal Cell Carcinoma 5 2026-01-22
Early detection of triple negative breast cancer relapse (CUPCAKE) Recruiting

2022-501562-22-01 Triple-negative breast cancer (TNBC) patients at high r 4 2026-01-05
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants with Prostate Cancer Recruiting

2024-517653-27-00 Prostate Cancer 4 2025-12-17
A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep… Recruiting

2024-513586-39-00 Prostate Cancer 5 2025-12-10
Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Recruiting

2025-520555-89-00 Metastatic castration-resistant prostate cancer (mCRPC) 5 2025-11-14
Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced… Recruiting

2024-519871-24-00 Breast cancer 10 2025-11-11
Clinical trial evaluating the activity of zanidatamab for the treatment of patients with solid tumors with an alteration of the HER2 gene Recruiting

2025-522169-31-00 Adult Patients with HER2-IHC3+ selected solid cancers ( 4 2025-10-30
Fluid administration in ketoacidosis Recruiting

2024-511513-37-00 Diabetic keto-acidosis 6 2025-10-23
A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First-Line Treatment o… Recruiting

2023-508056-19-00 HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Profi 5 2025-10-02
A short-term preoperative, window-of-opportunity study, evaluating activity and safety of Elacestrant monotherapy as compared to Elacestrant… Recruiting

2024-520051-24-00 Breast cancer 4 2025-09-30
EORTC 2022-MG: Treatment with tebentafusp or observation for patients with melanoma of the eye after surgery or radiation (ATOM Trial) Recruiting

2023-510333-28-00 Uveal Melanoma 5 2025-08-20
Testing ivonescimab versus FOLFOX in advanced biliary tract cancer patients Recruiting

2024-515875-36-00 Advanced biliary tract cancer (BTC) 4 2025-08-18
Detection of tumour DNA in the blood of patients receiving standard therapy for hormone receptor-positive (HR+) HER2 low expression (HER2 lo… Recruiting

2024-515349-41-00 Metastatic Breast Cancer HR+, HER2- 4 2025-07-29
Personalizing the use of pembrolizumab for patients who have a strong response in early triple negative breast cancer Recruiting

2024-515787-31-00 Patient with early triple-negative breast cancer (TNBC) 5 2025-07-18
Evaluating ivonescimab as a potential treatment for pleural mesothelioma patients whose cancer has returned after previous immunotherapy and… Recruiting

2024-519052-82-00 pleural mesothelioma 4 2025-06-30
EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting

2023-506817-23-01 Metastatic hormone naïve prostate cancer (mHNPC) 5 2025-05-23